本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Viking Therapeutics, Inc.

35.20
-0.3100-0.87%
盤後35.470.2712+0.77%19:57 EDT
成交量:247.87萬
成交額:8,790.50萬
市值:40.68億
市盈率:-11.03
高:36.35
開:35.85
低:34.97
收:35.51
52周最高:43.15
52周最低:22.96
股本:1.16億
流通股本:1.10億
量比:1.37
換手率:2.25%
股息:- -
股息率:- -
每股收益(TTM):-3.1920
每股收益(LYR):-3.1920
淨資產收益率:-47.34%
總資產收益率:-30.27%
市淨率:6.36
市盈率(LYR):-11.03

資料載入中...

2025/04/23

重要事件披露

Form 8-K - Current report
2025/04/23

重要事件披露

Form 8-K - Current report
2025/04/09

SEC問詢函

Form CORRESP - Correspondence
2025/03/11

重要事件披露

Form 8-K - Current report
2025/02/26

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/05

重要事件披露

Form 8-K - Current report
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

關聯方擬減持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 擬減持2000股,總價約13.73萬美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

關聯方擬減持公告

Form 144 | Viking Therapeutics高管Greg Zante擬減持131687股,總價約1028萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 擬減持11000股,總價約88.94萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Singleton擬減持16000股,總價約127萬美元
2024/10/23

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities